Cellect Biotechnology Ltd. Warrants to Purchase ADRs
APOPW
APOPW was delisted on the 3rd of August, 2021.
1 hedge funds and large institutions have $13K invested in Cellect Biotechnology Ltd. Warrants to Purchase ADRs in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
1,200% more capital invested
Capital invested by funds: $1K → $13K (+$12K)
0% more funds holding
Funds holding: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.1K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $13K | +$13.1K | +59,659 | +2,095% |
|
APOPW Hedge Fund Activity: Q2 2021 in Review
1 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) for Q2 2021, worth a combined $13K — up 1,200% from $1K a quarter earlier.
Fund positioning in APOPW was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $13.1K.
- 1 institutional investor held Cellect Biotechnology Ltd. Warrants to Purchase ADRs (APOPW) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $13K of Cellect Biotechnology Ltd. Warrants to Purchase ADRs stock for Q2 2021, up 1,200% quarter-over-quarter.
- 0 funds opened new Cellect Biotechnology Ltd. Warrants to Purchase ADRs positions in Q2 2021 and 0 closed out.
- The largest Cellect Biotechnology Ltd. Warrants to Purchase ADRs buyer in Q2 2021 was UBS Group, an estimated $13.1K added.
Based on aggregated 13F filings for Q2 2021.